Synergizing vaccinations with therapeutics for measles eradication

Expert Opinion on Drug Discovery

Volumn 9, Issue 2, 2014, Pages 201-214

  Plemper, Richard K ^a   Hammond, Anthea L ^b  

^a GEORGIA STATE UNIVERSITY   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

Anti virals; Measles eradication; Measles virus; Post exposure prophylaxis

Indexed keywords

MEASLES VACCINE;

ANXIETY; COST EFFECTIVENESS ANALYSIS; DISEASE ERADICATION; DRUG EFFICACY; DRUG SAFETY; ENVIRONMENTAL TEMPERATURE; EUROPE; HERD IMMUNITY; HUMAN; MEASLES; MEASLES VACCINATION; MEASLES VIRUS; POST EXPOSURE PROPHYLAXIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; TREATMENT REFUSAL; VIRUS RESISTANCE; VIRUS TRANSMISSION;

ANIMALS; ANTIVIRAL AGENTS; DISEASE ERADICATION; DRUG RESISTANCE, VIRAL; HUMANS; MEASLES; MEASLES VACCINE; VACCINATION;

EID: 84893096118     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2014.867324     Document Type: Review

References (147)

1. Cima G. Rinderpest eradicated. International organizations declare "cattle plague" dead. J Am Vet Med Assoc 2011;239:11-15
2. OIE declares rinderpest eradicated. Vet Rec 2011;168:573
3. Rinderpest officially eradicated. Vet Rec 2011;169:3
4. Moss WJ, Griffin DE. Measles. Lancet 2012;379:153-64
5. Moss WJ, Griffin DE. Global measles elimination. Nat Rev Microbiol 2006;4:900-8
6. Griffin DE. Measles virus. In: Knipe DM, Howley PM, editors. Fields virology. 5th edition. Volume 1. Wolters Kluwer/Lippincott Williams & Wilkins; Philadelphia: 2007. p. 1551-85
7. Hethcote HW. The mathematics of infectious disease. SIAM Rev 2000;42:599-653
8. Christensen PE, Schmidt H, Bang HO, et al. An epidemic of measles in southern Greenland, 1951; measles in virgin soil. II. The epidemic proper. Acta Med Scand 1953;144:430-49
9. Strebel PM, Cochi SL, Hoekstra E, et al. A world without measles. J Infect Dis 2011;204(Suppl 1):S1-3
10. de Vries RD, Mesman AW, Geijtenbeek TB, et al. The pathogenesis of measles. Curr Opin Virol 2012;2:248-55
11. Lemon K, de Vries RD, Mesman AW, et al. Early target cells of measles virus after aerosol infection of non-human primates. PLoS Pathog 2011;7:e1001263
12. de Vries RD, Lemon K, Ludlow M, et al. In vivo tropism of attenuated and pathogenic measles virus expressing green fluorescent protein in macaques. J Virol 2010;84:4714-24
13. Permar SR, Klumpp SA, Mansfield KG, et al. Limited contribution of humoral immunity to the clearance of measles viremia in rhesus monkeys. J Infect Dis 2004;190:998-1005
14. Griffin DE. Measles virus-induced suppression of immune responses. Immunol Rev 2010;236:176-89
15. Hirsch RL, Griffin DE, Johnson RT, et al. Cellular immune responses during complicated and uncomplicated measles virus infections of man. Clin Immunol Immunopathol 1984;31:1-12
16. Avota E, Avots A, Niewiesk S, et al. Disruption of Akt kinase activation is important for immunosuppression induced by measles virus. Nat Med 2001;7:725-31
17. Moss WJ, Ryon JJ, Monze M, et al. Differential regulation of interleukin (IL)-4, IL-5, and IL-10 during measles in Zambian children. J Infect Dis 2002;186:879-87
18. Griffin DE, Ward BJ. Differential CD4 T cell activation in measles. J Infect Dis 1993;168:275-81
19. Griffin DE, Cooper SJ, Hirsch RL, et al. Changes in plasma IgE levels during complicated and uncomplicated measles virus infections. J Allergy Clin Immunol 1985;76:206-13
20. Griffin DE, Oldstone MB. Measles. History and basic biology. Introduction. Curr Top Microbiol Immunol 2009;329:1
21. Bellini WJ, Rota PA. Biological feasibility of measles eradication. Virus Res 2011;162:72-9
22. McLean HQ, Fiebelkorn AP, Temte JL, et al. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2013;62:1-34
23. De Serres G, Markowski F, Toth E, et al. Largest measles epidemic in North America in a decade-Quebec, Canada, 2011: contribution of susceptibility, serendipity, and superspreading events. J Infect Dis 2013;207:990-8
24. WHO. Progress in global control and regional elimination of measles: 2001-2011. Wkly Epidemiol Rec 2013;88(3):29-36
25. WHO. Sixty-first World Health Assembly; Geneva, Switzerland. 2008
26. WHO. Proceedings of the Global Technical Consultation to assess the feasibility of measles eradication, 28-30 July 2010. J Infect Dis 2011;204(Suppl 1):S4-13
27. Saint-Victor DS, Omer SB. Vaccine refusal and the endgame: walking the last mile first. Philos Trans R Soc Lond B Biol Sci 2013;368:20120148
28. Hopkins DR. Smallpox: ten years gone. Am J Public Health 1988;78:1589-95
29. WHO. Measles. 2013. Available from: http://www.who.int/mediacentre/ factsheets/fs286/en/index.html
30. Simons E, Ferrari M, Fricks J, et al. Assessment of the 2010 global measles mortality reduction goal: results from a model of surveillance data. Lancet 2012;379:2173-8
31. Lazzarin A. Enfuvirtide: the first HIV fusion inhibitor. Expert Opin Pharmacother 2005;6:453-64
32. European Center for Disease Control and Prevention. Number of measles cases, 2011
33. Santibanez S, Mankertz A. Molecular surveillance shows progress in measles elimination process. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2013;56:1238-42
34. Wakefield AJ, Murch SH, Anthony A, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 1998;351:637-41
35. Murch SH, Anthony A, Casson DH, et al. Retraction of an interpretation. Lancet 2004;363:750
36. Madsen KM, Hviid A, Vestergaard M, et al. A population-based study of measles, mumps, and rubella vaccination and autism. N Engl J Med 2002;347:1477-82
37. DeStefano F, Thompson WW. MMR vaccine and autism: an update of the scientific evidence. Expert Rev Vaccines 2004;3:19-22
38. Goodson JL, Chu SY, Rota PA, et al. Research priorities for global measles and rubella control and eradication. Vaccine 2012;30:4709-16
39. Brown KF, Long SJ, Ramsay M, et al. U.K. parents' decision-making about measles-mumps-rubella (MMR) vaccine 10 years after the MMR-autism controversy: a qualitative analysis. Vaccine 2012;30:1855-64
40. Smith PJ, Humiston SG, Marcuse EK, et al. Parental delay or refusal of vaccine doses, childhood vaccination coverage at 24 months of age, and the Health Belief Model. Public Health Rep 2011;126(Suppl 2):135-46
41. Black S, Rappuoli R. A crisis of public confidence in vaccines. Sci Transl Med 2010;2:61mr61
42. Centers for Disease Control and Prevention. Measles - United States, 2011. MMWR Morb Mortal Wkly Rep 2012;61:253-7
43. LeBaron CW, Beeler J, Sullivan BJ, et al. Persistence of measles antibodies after 2 doses of measles vaccine in a postelimination environment. Arch Pediatr Adolesc Med 2007;161:294-301
44. Larson HJ, Cooper LZ, Eskola J, et al. Addressing the vaccine confidence gap. Lancet 2011;378:526-35
45. Griffin DE, Pan CH, Moss WJ. Measles vaccines. Front Biosci 2008;13:1352-70
46. National Advisory Committee on Immunization. Canadian immunization guide. 5th edition. Health Canada; Ottawa: 1998. p. 118-24
47. King A, Varughese P, De Serres G, et al. Measles elimination in Canada. J Infect Dis 2004;189(Suppl 1):S236-42
48. Boulianne N, Audet D, Ouakki M; Quebec City, Canada: Institut National de Santé Publique du Québec. Enquête sur la couverture vaccinale des enfants de 1 an et 2 ans au Québec en 2006. 2007. Available from: http://www.inspq. qc.ca/pdf/publications/678-Vaccination Enfantsen2006.pdf
49. Boulianne N, Bradet R, Audet D, et al. Quebec City, Canada: Institut National de Santé Publique du Québec. Enquête sur la couverture vaccinale des enfants de 1 an et 2 ans au Québec en 2008. 2009. Available from: http://www.inspq. qc.ca/pdf/publications/1045- CouverturVaccinEnfants1et2Ans2008.pdf
50. Boulianne N, Bradet R, Audet D, et al. Quebec City, Canada: Institut National de Santé Publique du Québec. Enquête sur la couverture vaccinale des enfants de 1 an et 2 ans au Québec en 2010. 2011. Available from: http://www.inspq. qc.ca/pdf/publications/1318-Enquete CouvVaccinEnfants1Et2AnsQc2010.pdf
51. Putz MM, Bouche FB, de Swart RL, et al. Experimental vaccines against measles in a world of changing epidemiology. Int J Parasitol 2003;33:525-45
52. Mossong J, Nokes DJ, Edmunds WJ, et al. Modeling the impact of subclinical measles transmission in vaccinated populations with waning immunity. Am J Epidemiol 1999;150:1238-49
53. Mossong J, O'Callaghan CJ, Ratnam S. Modelling antibody response to measles vaccine and subsequent waning of immunity in a low exposure population. Vaccine 2000;19:523-9
54. Ganellin CR, Jefferis R, Roberts SM. Introduction to biological and small molecule drug research and development: theory and case studies. Academic Press; Oxford, UK: 2013
55. de Vries RD, McQuaid S, van Amerongen G, et al. Measles immune suppression: lessons from the macaque model. PLoS Pathog 2012;8:e1002885
56. von Messling V, Milosevic D, Cattaneo R. Tropism illuminated: lymphocyte-based pathways blazed by lethal morbillivirus through the host immune system. Proc Natl Acad Sci USA 2004;101:14216-21
57. Centers for Disease Control and Prevention. Global Health - Measles, Rubella, and CRS. Available from: http://www.cdc.gov/globalhealth/measles/ why/infographic.htm
58. Talbird SE, Brogan AJ, Winiarski AP. Oseltamivir for influenza postexposure prophylaxis: economic evaluation for children aged 1-12 years in the U.S. Am J Prevent Med 2009;37:381-8
59. Barclay AJ, Foster A, Sommer A. Vitamin A supplements and mortality related to measles: a randomised clinical trial. Br Med J (Clin Res Ed) 1987;294:294-6
60. World Health Organization (WHO). Strategies for reducing global measles mortality. Wkly Epidemiol Rec 2000;75:411-16
61. D'Souza RM, D'Souza R. Vitamin A for treating measles in children. Cochrane Database Syst Rev 2002;CD001479
62. Villamor E, Fawzi WW. Vitamin A supplementation: implications for morbidity and mortality in children. J Infect Dis 2000;182(Suppl 1):S122-33
63. Stogner SW, King JW, Black-Payne C, et al. Ribavirin and intravenous immune globulin therapy for measles pneumonia in HIV infection. South Med J 1993;86:1415-18
64. Hosoya M. Therapy and prognosis in subacute sclerosing panencephalitis. Nippon Rinsho 2007;65:1483-6
65. Tomoda A, Nomura K, Shiraishi S, et al. Trial of intraventricular ribavirin and interferon-alpha combination therapy for subacute sclerosing panencephalitis (SSPE) in Japan. No To Hattatsu 2003;35:321-6
66. Gururangan S, Stevens RF, Morris DJ. Ribavirin response in measles pneumonia. J Infect 1990;20:219-21
67. Forni AL, Schluger NW, Roberts RB. Severe measles pneumonitis in adults: evaluation of clinical characteristics and therapy with intravenous ribavirin. Clin Infect Dis 1994;19:454-62
68. Fernandez H, Banks G, Smith R. Ribavirin: a clinical overview. Eur J Epidemiol 1986;2:1-14
69. Campbell C, Levin S, Humphreys P, et al. Subacute sclerosing panencephalitis: results of the Canadian Paediatric Surveillance Program and review of the literature. BMC Pediatr 2005;5:47
70. Hara S, Kimura H, Hoshino Y, et al. Combination therapy with intraventricular interferon-alpha and ribavirin for subacute sclerosing panencephalitis and monitoring measles virus RNA by quantitative PCR assay. Brain Dev 2003;25:367-9
71. del Toro-Riera M, Macaya-Ruiz A, Raspall-Chaure M, et al. Subacute sclerosing panencephalitis: combined treatment with interferon alpha and intraventricular ribavirin. Rev Neurol 2006;42:277-81
72. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006;55:1350-9
73. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65
74. Atkinson W, Hamborsky J, McIntyre L, et al. Centers for Disease Control and Prevention. Epidemiology and prevention of Vaccine-Preventable diseases. 10th edition. Public Health Foundation; Washington DC, USA: 2008
75. Koschel K, Brinckmann U, Hoyningen-Huene VV. Measles virus antisense sequences specifically cure cells persistently infected with measles virus. Virology 1995;207:168-78
76. Bell AF, Whitton JL, Fujinami RS. Antisense-mediated resistance to measles virus infection in HeLa cells. J Infect Dis 1997;176:258-61
77. Sleeman K, Stein DA, Tamin A, et al. Inhibition of measles virus infections in cell cultures by peptide-conjugated morpholino oligomers. Virus Res 2009;140:49-56
78. Miller FA, Dixon GJ, Arnett G, et al. Antiviral activity of carbobenzosy di- and tripeptides on measles virus. Appl Microbiol 1968;16:1489-96
79. Nicolaides E, DeWald H, Lipnik M, et al. Potential antiviral agents. Carbobenzoxy di- and tripeptides active against measles and herpes viruses. J Med Chem 1968;11:74-9
80. Lambert DM, Barney S, Lambert AL, et al. Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. Proc Natl Acad Sci USA 1996;93:2186-91
81. Welsch JC, Talekar A, Mathieu C, et al. Fatal measles infection prevented by brain-penetrant fusion inhibitors. J Virol 2013;87(24):13785-94
82. Parker ME, Chabot S, Ward BJ, et al. Traditional dietary additives of the Maasai are antiviral against the measles virus. J Ethnopharmacol 2007;114:146-52
83. Petricevich VL, Mendonca RZ. Inhibitory potential of Crotalus durissus terrificus venom on measles virus growth. Toxicon 2003;42:143-53
84. Wachsman MB, Ramirez JA, Galagovsky LR, et al. Antiviral activity of brassinosteroids derivatives against measles virus in cell cultures. Antivir Chem Chemother 2002;13:61-6
85. Olila D, Olwa O, Opuda-Asibo J. Screening extracts of Zanthoxylum chalybeum and Warburgia ugandensis for activity against measles virus (Swartz and Edmonston strains) in vitro. Afr Health Sci 2002;2:2-10
86. Cos P, Hermans N, De Bruyne T, et al. Further evaluation of Rwandan medicinal plant extracts for their antimicrobial and antiviral activities. J Ethnopharmacol 2002;79:155-63
87. Huang SP, Shieh GJ, Lee L, et al. Inhibition effect of shengma-gegen-tang on measles virus in Vero cells and human peripheral blood mononuclear cells. Am J Chin Med 1997;25:89-96
88. McWhorter JH. Spicebush. A Cherokee remedy for the measles. N C Med J 1996;57:306
89. Lin YM, Flavin MT, Schure R, et al. Antiviral activities of biflavonoids. Planta Med 1999;65:120-5
90. Kurokawa M, Ochiai H, Nagasaka K, et al. Antiviral traditional medicines against herpes simplex virus (HSV-1), poliovirus, and measles virus in vitro and their therapeutic efficacies for HSV-1 infection in mice. Antiviral Res 1993;22:175-88
91. Hayashi T, Hayashi K, Maeda M, et al. Calcium spirulan, an inhibitor of enveloped virus replication, from a bluegreen alga Spirulina platensis. J Nat Prod 1996;59:83-7
92. Barnard DL, Stowell VD, Seley KL, et al. Inhibition of measles virus replication by 5'-nor carbocyclic adenosine analogues. Antivir Chem Chemother 2001;12:241-50
93. Li W, Yin X, Schneller SW. 5'-Fluoro- 5'-deoxyaristeromycin. Bioorg Med Chem Lett 2008;18:220-2
94. Zhang N, Chen HM, Sood R, et al. In vitro inhibition of the measles virus by novel ring-expanded ('fat') nucleoside analogues containing the imidazo[4,5-e] diazepine ring system. Bioorg Med Chem Lett 2002;12:3391-4
95. Barnard DL, Xu ZQ, Stowell VD, et al. Coumarins and pyranocoumarins, potential novel pharmacophores for inhibition of measles virus replication. Antivir Chem Chemother 2002;13:39-59
96. Santagati NA, Bousquet E, Garozzo A, et al. Synthesis and anti-measles virus activity of new isoquinolin-4-one derivatives. Farmaco 2003;58:1217-25
97. Plemper RK, Doyle J, Sun A, et al. Design of a small-molecule entry inhibitor with activity against primary measles virus strains. Antimicrob Agents Chemother 2005;49:3755-61
98. Plemper RK, Erlandson KJ, Lakdawala AS, et al. A target site for template-based design of measles virus entry inhibitors. Proc Natl Acad Sci USA 2004;101:5628-33
99. Sun A, Prussia A, Zhan W, et al. Nonpeptide inhibitors of measles virus entry. J Med Chem 2006;49:5080-92
100. Sun A, Chandrakumar N, Yoon JJ, et al. Non-nucleoside inhibitors of the measles virus RNA-dependent RNA polymerase complex activity: synthesis and in vitro evaluation. Bioorg Med Chem Lett 2007;17:5199-203
101. Sun A, Yoon JJ, Yin Y, et al. Potent non-nucleoside inhibitors of the measles virus RNA-dependent RNA polymerase complex. J Med Chem 2008;51:3731-41
102. White LK, Yoon JJ, Lee JK, et al. Nonnucleoside inhibitor of measles virus RNA-dependent RNA polymerase complex activity. Antimicrob Agents Chemother 2007;51:2293-303
103. Plemper RK, Snyder JP. Measles control-can measles virus inhibitors make a difference? Current Opin Investigat Drugs 2009;10:811-20
104. Barnard DL. Inhibitors of measles virus. Antivir Chem Chemother 2004;15:111-19
105. Yoon JJ, Krumm SA, Ndungu JM, et al. Target analysis of the experimental measles therapeutic AS-136A. Antimicrob Agents Chemother 2009;53:3860-70
106. Ndungu JM, Krumm SA, Yan D, et al. Non-nucleoside inhibitors of the measles virus RNA-dependent RNA polymerase: synthesis, structure-activity relationships, and pharmacokinetics. J Med Chem 2012;55:4220-30
107. Plemper RK. Cell entry of enveloped viruses. Curr Opin Virol 2011;1:92-100
108. Kilby JM, Hopkins S, Venetta TM, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998;4:1302-7
109. Kilby JM, Lalezari JP, Eron JJ, et al. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIVinfected adults. AIDS Res Hum Retroviruses 2002;18:685-93
110. De Clercq E. Antiviral drugs in current clinical use. J Clin Virol 2004;30:115-33
111. Doms RW, Moore JP. HIV-1 membrane fusion: targets of opportunity. J Cell Biol 2000;151:F9-14
112. Jamjian MC, McNicholl IR. Enfuvirtide: first fusion inhibitor for treatment of HIV infection. Am J Health Syst Pharm 2004;61:1242-7
113. Lamb RA, Parks GD. Paramyxoviridae: the viruses and their replication. In: Knipe DM, Howley PM, editors. Fields virology. 5th editon. Volume 1 Wolters; Kluwer/Lippincott Williams & Wilkins; Philadelphia: 2007. p. 1449-96
114. Domingo E, Holland JJ. Mutation rates and rapid evolution of RNA viruses. In: Morse SS, editor. The evolutionary biology of viruses. Raven Press Ltd; New York, NY, USA: 1994. p. 161-84
115. Zhang X, Rennick LJ, Duprex WP, et al. Determination of spontaneous mutation frequencies in measles virus under nonselective conditions. J Virol 2013;87:2686-92
116. Schrag SJ, Rota PA, Bellini WJ. Spontaneous mutation rate of measles virus: direct estimation based on mutations conferring monoclonal antibody resistance. J Virol 1999;73:51-4
117. De Clercq E. Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future. Chem Biodivers 2004;1:44-64
118. De Clercq E. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Res 1998;38:153-79
119. Peuchant O, Capdepont S, Ragnaud JM, et al. Primary resistance to enfuvirtide (T20) in recently HIV-1 infected, antiretroviral-naive patients from the ANRS Aquitaine Cohort. Antiviral Ther 2007;12:559-62
120. Lu J, Deeks SG, Hoh R, et al. Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis. J Acquir Immune Defic Synd 2006;43:60-4
121. Greenberg ML, Cammack N. Resistance to enfuvirtide, the first HIV fusion inhibitor. J Antimicrob Chemother 2004;54:333-40
122. Derdeyn CA, Decker JM, Bibollet-Ruche F, et al. Envelope-constrained neutralization- sensitive HIV-1 after heterosexual transmission. Science 2004;303:2019-22
123. Kabra SK, Lodha R. Antibiotics for preventing complications in children with measles. Cochrane Database Syst Rev 2013;8:CD001477
124. Rima BK, Duprex WP. Morbilliviruses and human disease. J Pathol 2006;208:199-214
125. Nasr JT, Andriola MR, Coyle PK. ADEM: literature review and case report of acute psychosis presentation. Pediatr Neurol 2000;22:8-18
126. ter Meulen V, Stephenson JR, Kreth HW. Subacute sclerosing panencephalitis. In: Fraenkel-Conrat H, Wagner RR, editors. Comprehensive virology. Plenum Press; New York, NY, USA: 1983. p. 105-59
127. Modlin JF, Jabbour JT, Witte JJ, et al. Epidemiologic studies of measles, measles vaccine, and subacute sclerosing panencephalitis. Pediatrics 1977;59:505-12
128. Bellini WJ, Rota JS, Lowe LE, et al. Subacute sclerosing panencephalitis: more cases of this fatal disease are prevented by measles immunization than was previously recognized. J Infect Dis 2005;192:1686-93
129. Turner A, Jeyaratnam D, Haworth F, et al. Measles-associated encephalopathy in children with renal transplants. Am J Transplant 2006;6:1459-65
130. Freeman AF, Jacobsohn DA, Shulman ST, et al. A new complication of stem cell transplantation: measles inclusion body encephalitis. Pediatrics 2004;114:e657-60
131. Billeter MA, Cattaneo R, Spielhofer P, et al. Generation and properties of measles virus mutations typically associated with subacute sclerosing panencephalitis. Ann NY Acad Sci 1994;724:367-77
132. Rima BK, Duprex WP. Molecular mechanisms of measles virus persistence. Virus Res 2005;111:132-47
133. Urbanska EM, Chambers BJ, Ljunggren HG, et al. Spread of measles virus through axonal pathways into limbic structures in the brain of TAP1 -/- mice. J Med Virol 1997;52:362-9
134. Lawrence DM, Patterson CE, Gales TL, et al. Measles virus spread between neurons requires cell contact but not CD46 expression, syncytium formation, or extracellular virus production. J Virol 2000;74:1908-18
135. Banyard AC, Parida S, Batten C, et al. Global distribution of peste des petits ruminants virus and prospects for improved diagnosis and control. J Gen Virol 2010;91:2885-97
136. Kitching RP. The economic significance and control of small ruminant viruses in North Africa and West Asia. In: Thompson FS, editor. Increasing small ruminant productivity in semi-arid areas. Kluwer Academic Publishers; Dordrecht, The Netherlands: 1988. p. 225-36
137. Meissner HC, Strebel PM, Orenstein WA. Measles vaccines and the potential for worldwide eradication of measles. Pediatrics 2004;114:1065-9
138. Reynolds MG, Damon IK. Outbreaks of human monkeypox after cessation of smallpox vaccination. Trends Microbiol 2012;20:80-7
139. Essbauer S, Pfeffer M, Meyer H. Zoonotic poxviruses. Vet Microbiol 2010;140:229-36
140. Bieringer M, Han JW, Kendl S, et al. Experimental adaptation of wild-type canine distemper virus (CDV) to the human entry receptor CD150. PLoS One 2013;8:e57488
141. Appel MJ, Shek WR, Shesberadaran H, et al. Measles virus and inactivated canine distemper virus induce incomplete immunity to canine distemper. Arch Virol 1984;82:73-82
142. Sanders R, Dabbagh A, Featherstone D. Risk analysis for measles reintroduction after global certification of eradication. J Infect Dis 2011;204(Suppl 1):S71-7
143. de Swart RL, Duprex WP, Osterhaus AD. Rinderpest eradication: lessons for measles eradication? Current Opin Virol 2012;2:330-4
144. Stittelaar KJ, de Swart RL, Osterhaus AD. Vaccination against measles: a neverending story. Expert Rev Vaccines 2002;1:151-9
145. Qiu W, Zheng Y, Zhang S, et al. Canine distemper outbreak in rhesus monkeys. China. Emerg Infect Dis 2011;17:1541-3
146. Osterhaus A. Catastrophes after crossing species barriers. Philos Trans R Soc Lond B Biol Sci 2001;356:791-3
147. Sun A, Prussia A, Zhan W, et al. Nonpeptide inhibitors of measles virus entry. J Med Chem 2006;49:5080-92